Latest Vancomycin Stories
Researchers identify the specific mechanism that triggers resistance to vancomycin.
NEW YORK, March 22 /PRNewswire/ -- Recent clinical tests demonstrate that antimicrobial copper is effective in significantly reducing the bacterial load in intensive care unit (ICU) patient rooms and on many individual objects in those rooms. Results from a U.S.
FLORENCE, Italy and EXTON, Pa., March 19 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of two abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.
WALTHAM, Mass., March 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs).
EXTON, Pa., March 16 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today that the company will provide a live audio webcast of its investor day event, focusing on Cinryze growth opportunities on Friday, March 19, 2010.
TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.
DURHAM, N.C., March 11 /PRNewswire/ -- bioMerieux - a world leader in the field of in vitro diagnostics - today announced the launch of the first Food and Drug Administration (FDA) cleared chromID(TM) VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE).
EXTON, Pa., March 2 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Cowen and Company 30th Annual Healthcare Conference at 11:05 A.M. ET on Tuesday, March 9, 2010.
EXTON, Pa., Feb. 17 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) fourth quarter and year end financial results for 2009 are expected to be released on Wednesday, February 24, 2010 before the open of the U.S.
Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...
Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...
- The act of sweetening by admixture of some saccharine substance.